GUILLAIN-BARRE SYNDROME RELATED TO THE APPLICATION OF VACCINE AGAINST SARS-CoV2 AND SEASONAL INFLUENZA. CASE REPORT

Authors

  • Juan Carlos López-Hernández Departamento de Urgencias Neurológicas / Clínica de Enfermedades Neuromusculares. Instituto Nacional de Neurología y Neurocirugía
  • Jorge López-Alderete Departamento de Neurología. Instituto Nacional de Neurología y Neurocirugía
  • Angel Escamilla-Ramírez Instituto Nacional de Neurología y Neurocirugía
  • Artemio Rosiles-Abonce Departamento de Neurología. Instituto Nacional de Neurología y Neurocirugía
  • Arturo Violante-Villanueva Departamento de Urgencias Neurológicas. Instituto Nacional de Neurología y Neurocirugía
  • Alonso Gutiérrez-Romero Departamento de Neurología. Instituto Nacional de Neurología y Neurocirugía
  • Steven Vargas-Cañas Clínica de Enfermedades Neuromusculares. Instituto Nacional de Neurología y Neurocirugía

DOI:

https://doi.org/10.31157/an.v27i2.348

Keywords:

SARS-CoV2, Influenza, Guillain Barre Syndrome, Vaccination, AIDP

Abstract

Summary: Guillain Barre Syndrome (GBS) is the leading cause of acute flaccid paralysis in the world. In the course of the pandemic influenza virus in previous decades and, currently, SARS-CoV2, an increased number of GBS cases have been reported coinciding with mass vaccination. Recently, vaccination against these two viruses has been implemented in the vaccination schedules of the adult population. Objective: to report a case of GBS related to vaccination against seasonal influenza virus and SARS-CoV2. We present the case of a 53-year-old woman with no history of infectious disease, who, after vaccination against seasonal influenza and SARS-CoV2 (Oxford/AstraZeneca) within 22 days of each other, began with progressive symptoms of weakness predominantly in the lower limbs, ascending. Clinically, GBS was integrated. In the paraclinical studies, she had a lumbar puncture with albumin-cytological dissociation, with a neuroconduction study that fulfils the criteria for an AIDP variant. Conclusion: to our knowledge, this is the first case of GBS related to both types of vaccine.

References

[1] van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469–82. https://doi.org/10.1038/nrneurol.2014.121.
[2] López-Hernández JC, Colunga-Lozano LE, Garcia-Trejo S, Gomez-Figueroa E, Delgado-Garcia G, Bazán-Rodríguez L, et al. Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a single center experience. J Clin Neurosci Off J Neurosurg Soc Australas 2020;80:292–7. https://doi.org/10.1016/j.jocn.2020.04.059.
[3] Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599–612. https://doi.org/10.1016/j.vaccine.2010.06.003.
[4] López-Hernández J, Lisette B-R, Adib J de S, Eunice M-J, Elizabeth L-M, Erika G-L, et al. Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association? Neuroimmunol Reports 2022;2:100050. https://doi.org/10.1016/j.nerep.2021.100050.
[5] García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021;230:108818. https://doi.org/10.1016/j.clim.2021.108818.
[6] Asia C, Asia W. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Relev Epidemiol Hebd 2018;93:133–41.
[7] Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka K V, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780–8. https://doi.org/10.1002/ana.410440512.
[8] Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979;110:105–23. https://doi.org/10.1093/oxfordjournals.aje.a112795.
[9] Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol 2021;90:315–8. https://doi.org/10.1002/ana.26144.
[10] Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021;268:1133–70. https://doi.org/10.1007/s00415-020-10124-x.
[11] Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, Freitas Barboza IC, Vieira Silveira CG, et al. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review. Acta Neurol Scand 2021. https://doi.org/10.1111/ane.13575.
[12] Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984;119:841–79. https://doi.org/10.1093/oxfordjournals.aje.a113809.
[13] Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006;166:2217–21. https://doi.org/10.1001/archinte.166.20.2217.
[14] Kwong JC, Vasa PP, Campitelli MA, Hawken S, Wilson K, Rosella LC, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013;13:769–76. https://doi.org/10.1016/S1473-3099(13)70104-X.

Additional Files

Published

2022-05-26

How to Cite

López-Hernández, J. C. ., López-Alderete, J., Angel, Rosiles-Abonce, A. ., Violante-Villanueva, A. ., Gutiérrez-Romero, A. ., & Vargas-Cañas, S. . (2022). GUILLAIN-BARRE SYNDROME RELATED TO THE APPLICATION OF VACCINE AGAINST SARS-CoV2 AND SEASONAL INFLUENZA. CASE REPORT. Archivos De Neurociencias, 27(2), 47–51. https://doi.org/10.31157/an.v27i2.348

Issue

Section

Case report

Most read articles by the same author(s)